LS 174T Xenograft Model Service for Colon Cancer

The LS 174T xenograft model provides a robust, mucin-producing platform for evaluating therapeutic efficacy against colorectal adenocarcinoma in vivo. Alfa Cytology leverages this well-characterized cell line to deliver reproducible preclinical colon cancer xenograft studies, supporting your compound's journey from bench to IND-enabling data.

Overview of LS 174T Xenograft Model for Colon Cancer

The LS 174T cell line was established from a Duke's type B colorectal adenocarcinoma resected from a 58-year-old female patient. It is a variant of the parent LS-180 line, selected for superior subculture properties and robust tumorigenicity. LS 174T cells exhibit a partially differentiated epithelial phenotype with abundant microvilli, prominent intracytoplasmic mucin vacuoles, and constitutive MUC2 expression---features characteristic of mucinous colorectal carcinoma. Molecularly, the line harbors activating KRAS G12D and inactivating TP53 mutations, alongside APC loss-of-function, driving dysregulated Wnt/beta-catenin signaling with elevated MYC and CCND1 transcription. These cells also secrete high levels of carcinoembryonic antigen (CEA), interleukin-6 (IL-6), and interleukin-10 (IL-10), making the model particularly relevant for studies targeting tumor-associated glycoproteins and immunomodulatory cytokines. In vivo, LS 174T xenografts maintain mucin-secreting histology, moderate growth kinetics, and have been classified as CMS3/Goblet-like according to consensus molecular subtyping, faithfully recapitulating the iCMS3 epithelial subtype with low copy-number variation.

The LS 174T xenograft model has been extensively validated across subcutaneous, intraperitoneal, and orthotopic implantation settings. Subcutaneous tumors in immunodeficient mice (NOD/SCID or athymic nude strains) demonstrate reliable engraftment with preserved mucinous architecture, while orthotopic models via enema or surgical implantation achieve high tumor-take rates and enable regional metastasis studies. The model has served as a critical platform for evaluating antibody-drug conjugates against TAG-72, radiolabeled anti-CEA immunotherapy, angiogenesis inhibitors such as VEGFR2 tyrosine kinase inhibitors, and combination strategies targeting mTOR/JNK pathways. Its dense extracellular matrix and mucin barrier also make LS 174T uniquely suited for investigating drug-penetration limitations and testing mucolytic or immune-modulatory combination regimens.

Figure 1. A summary model. Let-7a inhibits LS-174T cells proliferation and metastasis by regulating TGF-beta/Smad signaling. (Cao, W, et al., 2021)

Cell Line Information: LS 174T

The following table summarizes the key biological, molecular, and technical characteristics of the LS 174T cell line:

Our Services

Alfa Cytology offers comprehensive LS 174T xenograft model services tailored to your preclinical research objectives. From cell line authentication and subcutaneous or orthotopic tumor establishment to longitudinal monitoring, endpoint histopathology, and molecular profiling, our team ensures rigorous quality control and reproducible data generation. Whether you are evaluating single-agent efficacy, combination regimens, or novel delivery strategies targeting mucin-rich tumor microenvironments, we provide customizable study designs with flexible dosing schedules, multiple immunodeficient mouse strains, and integrated biomarker analysis to accelerate your drug development pipeline.

Workflow of LS 174T Xenograft Model Construction

Construction of the LS 174T xenograft model follows a standardized, quality-controlled workflow designed to ensure reproducible tumor growth, reliable therapeutic readouts, and compliance with preclinical study standards. Each step is optimized to preserve the mucin-producing, partially differentiated phenotype that defines this model's biological relevance.

1. Cell Culture and Expansion: LS 174T cells are maintained in DMEM supplemented with 10% fetal bovine serum under standard adherent culture conditions. Cells are expanded to the required scale while maintaining low passage number to preserve genetic and phenotypic stability.
2. Quality Control and Authentication: Prior to in vivo use, cells undergo STR profiling for authentication, mycoplasma screening, and viability assessment (>95% by trypan blue exclusion). Morphological verification confirms retained epithelial characteristics and mucin vacuolation.
3. Cell Harvest and Preparation: On the day of implantation, cells are harvested using trypsinization, washed in PBS, and resuspended at the appropriate concentration. For enhanced engraftment, cells may be mixed with Matrigel or basement membrane matrix to support initial tumor microenvironment formation.
4. Animal Preparation and Injection: Immunodeficient mice (athymic nude or NOD/SCID, 6-8 weeks old) are acclimatized and randomized into study groups. LS 174T cells are implanted subcutaneously into the flank (typically 1 x 10^6 to 5 x 10^6 cells in 100-200 µL) or via orthotopic/enema routes depending on study objectives.
5. Tumor Monitoring and Measurement: Tumor growth is monitored twice weekly using digital calipers, with volume calculated via the modified ellipsoid formula (length x width^2 x 0.5). For advanced studies, bioluminescence imaging or MRI may be employed for non-invasive longitudinal tracking.
6. Endpoint Analysis and Tissue Collection: Upon reaching predetermined endpoint criteria (tumor volume, study duration, or ethical limits), mice are euthanized. Tumors and relevant organs are harvested, weighed, and processed for histopathology (H&E, IHC for CEA/MUC2/TAG-72), molecular profiling (RNA-seq, Western blot), and pharmacokinetic analysis.

Figure 2: Schematic workflow illustrating the derivation and construction of the LS 174T Xenograft Model at Alfa Cytology.

Case Study-LS 174T Xenograft Model Development

In a representative preclinical engagement, Alfa Cytology established subcutaneous LS 174T xenografts in immunodeficient mice to evaluate a novel therapeutic candidate targeting mucin-associated tumor antigens. Tumors achieved consistent engraftment with moderate growth kinetics, maintaining characteristic mucin-rich histology and elevated CEA expression throughout the study duration. Treatment arms demonstrated measurable differences in tumor growth inhibition relative to vehicle controls, with endpoint analyses revealing modulation of key signaling pathways and biomarker expression. Detailed quantitative data, including tumor growth curves, pharmacokinetic profiles, and histopathological scoring, are available upon request under confidentiality agreements.

Why Choose Alfa Cytology?

Alfa Cytology combines deep oncology expertise with rigorous operational standards to deliver LS 174T xenograft data you can trust for critical preclinical decisions.

• Validated cell line sourcing with STR authentication and mycoplasma-free certification for every study.
• Flexible model configurations including subcutaneous, orthotopic, and patient-derived xenograft co-engraftment options.
• Integrated biomarker analysis covering CEA, MUC2, TAG-72, and custom IHC panels tailored to your mechanism of action.
• Real-time study monitoring with digital caliper tracking, bioluminescence imaging, and optional MRI for longitudinal assessment.
• GLP-compliant histopathology and molecular profiling services with comprehensive study reports suitable for IND submissions.
• Dedicated project management ensuring transparent communication, milestone-driven timelines, and reproducible experimental outcomes.

Contact Us

Ready to advance your colon cancer therapeutic program with a validated LS 174T xenograft model? Contact us today to discuss your study requirements, receive a customized proposal, and learn how Alfa Cytology can accelerate your preclinical development timeline. Reach out to our scientific team for a confidential consultation and access to detailed case study data.

For research use only. Not intended for any clinical use.